Paul ‏ Keown

Dr. Keown is founder and CEO of Syreon Corporation, integrating global expertise in Precision Medicine, Molecular Diagnostics and Data Sciences for clinical research in personalized healthcare. Syreon provides a full suite of adaptive clinical trials, health economics and outcomes research ensuring safe, effective and value-driven clinical use of innovative therapies in more than 40 countries. Syreon partners with an elite portfolio of global pharmaceutical corporations and early-stage biotech companies to speed the evaluation of new therapies and improve health outcomes. Its expert research services identify precise therapeutic needs, rapidly evaluate new health interventions, monitor clinical use and define optimal economic value in today's competitive health environment. Syreon scientists have contributed to many groundbreaking innovations, from the first blockbuster signal inhibitors, chimeric and humanized monoclonals, recombinant human proteins and companion diagnostics to the developing fields of immuno-oncology, stem cell therapeutics and other recent initiatives in precision medicine. Syreon's head offices in North America and Europe coordinate an international network of regional offices and expert research teams providing personal support and professional coordination to clients, investigators, providers, purchasers and payers. Our services through all phases of study planning, operation, analysis and reporting ensure safe, effective and value-driven clinical use. Dr. Keown trained in medicine in Europe and North America, and holds doctorates in medicine and science along with an MBA. He is Professor of Medicine at the University of British Columbia, Director of Immunology, past Chair of the Canadian Human Proteome Consortium and a member of the University Senate. He has served as a leading clinician and principal investigator, and in many senior executive positions in healthcare and an adviser to government and industry.